Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
Share: U.S. FDA Granted Fast Track Designation in 2018 Trial Expected to Enroll 300-400 Patients at Approximately 165 Sites in the U.S. and Europe in Simplified Adaptive Trial Design Conference Call and Webcast Today at 8:30 a.m. ET HOUSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer (PROC). The trial is evaluating the efficacy of AVB-500 in com...